Italpreziosi Achieves LMBA Silver Good Delivery AccreditationAREZZO, Italy, May 22, 2026 (GLOBE NEWSWIRE) -- Italpreziosi S.p.A. is pleased to announce its official inclusion in the LBMA Silver Good Delivery List, one of the most prestigious international standards in the precious metals industry.
Together for Steatotic Liver Disease - The Hidden NCDs: SLD as the Next Global Public Health PriorityGeneva, Switzerland, May 22, 2026 (GLOBE NEWSWIRE) -- Yesterday, Global Liver Institute (GLI), in collaboration with the Egyptian Ministry of Health and Population, convened a high-level policy event, on the sidelines of the Seventy-Ninth World Health Assembly (WHA79) to translate this global policy milestone into coordinated action.
ARKAY Launches New 200 ml Mocktail Tetra Pack Collection: A Convenient, Alcohol-Free Grab-and-Go Beverage for Modern ConsumersMIAMI, May 22, 2026 (GLOBE NEWSWIRE) -- ARKAY is proud to announce the launch of its new 200 ml Mocktail Tetra Pack Collection, a convenient, ready-to-drink line created for today’s fast-moving consumers who are looking for great taste, portability, and alcohol-free options.
Slovenian Tourist Board: Slovenia to Host the 2026 UEC Road European Championships This OctoberThe largest cycling event in Slovenian history will bring 800 riders from 50+ countries to the roads of Slovenia — including Slovenian cycling stars Tadej Pogačar and Primož Roglič
Aegon appoints Jennifer Palmieri as Chief Human Resources OfficerSchiphol, May 22, 2026 - Aegon today announces that Jennifer Palmieri will join Aegon as Chief Human Resources Officer and member of Aegon’s Executive Committee, effective June 29, 2026. She will succeed Holly Waters who will retire as of June 1, 2026.
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian CancerOSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
FRO – First Quarter 2026 ResultsFRONTLINE PLC REPORTS RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026
VALLOUREC AND SYNGULAR SOLUTIONS SIGN A MEMORANDUM OF UNDERSTANDING TO ACCELERATE THE DEVELOPMENT OF BIOENERGY WITH CARBON CAPTURE AND STORAGE PROJECTS VALLOUREC AND SYNGULAR SOLUTIONS SIGN A MEMORANDUM OF UNDERSTANDING TO ACCELERATE THE DEVELOPMENT OF BIOENERGY WITH CARBON CAPTURE AND STORAGE PROJECTS
NervGen Announces Pricing of US$60.0 Million Public Offering of SecuritiesVANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (
NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, today announced the pricing of an underwritten public offering of 24,000,000 common shares and accompanying warrants to purchase up to 24,000,000 common shares. The common shares are being sold at a public offering price of US$2.50 per common share and accompanying warrant. Each accompanying warrant has an exercise price of US$3.68 per common share, and will be immediately exercisable from the date of issuance, and will expire five years from the date of issuance.
Yimutian Inc. Announces Submission of Hearing Request to Nasdaq and Proactive Measures to Regain Full ComplianceBEIJING, May 21, 2026 (GLOBE NEWSWIRE) -- Yimutian Inc. (Nasdaq: YMT) (“Yimutian” or the “Company”), a leading agricultural digital service company in China, today announced that it has formally submitted a hearing request to the Hering Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) on May 20, 2026, Eastern Time.
Medline Inc. announces pricing of upsized secondary offering of Class A common stockNORTHFIELD, Ill., May 21, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of its upsized secondary offering of 72,554,594 shares of Medline Inc.’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) at a price to the public of $37.00 per share. The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 10,883,189 shares of Medline’s Class A common stock. The offering is expected to close on May 28, 2026, subject to customary closing conditions.
GLOBAL’s AcceptAbility Gala Raises $430,000 for Down Syndrome Research and Medical Care as Celebrities and Congressional Leaders Rally Behind the CauseGlobal Down Syndrome Foundation Honored Sen. Shelley Moore Capito and Rep. Paul Tonko at Event that Featured Award-Winning Multiplatinum Artist Rachel Platten and Inclusive Dance Team
AIFA Provides Update on Nasdaq Notice and Filing of Annual Report, Clearing Key Pathways for Strategic TransformationNEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- All In FutureTech Alliance, Inc. (Nasdaq: AGAE) (the “Company” or “AIFA”) today provided an update regarding the previously received notice from the Listing Qualifications Department of The Nasdaq Stock Market.
Liminatus Pharma Announces Nasdaq Delisting NotificationFULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company received a delisting notice from The Nasdaq Stock Market LLC (“Nasdaq”).
Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026ROCKVILLE, Md. and SUZHOU, China, May 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that six abstracts from its clinical studies, selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, are now available on ASCO’s official website. Three of the six studies have been selected for rapid oral presentations, and three as poster presentation. These abstracts report data from ongoing studies evaluating the company’s three lead drug candidates, including BCR-ABL inhibitor olverembatinib(HQP1351); Bcl-2 inhibitor lisaftoclax (APG-2575); and MDM2-p53 inhibitor alrizomadlin (APG-115).
Rocket Lab Awarded $90M Contract to Build GEO Satellites Hosting Space Domain Awareness Payload for U.S. Space ForceAward marks Rocket Lab's first satellite production program for geostationary orbit and continues a Space Systems Command program for development and delivery on orbit of two Heimdall prototype payloads by Rocket Lab Optical Systems
PHR SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Phreesia, Inc. Investors - Contact Kirby McInerney LLP by July 13, 2026NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Phreesia, Inc. (“Phreesia” or the “Company”) (
NYSE:PHR) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual MeetingHONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, USA.
Z INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Zillow Group, Inc.NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Zillow Group, Inc. (“Zillow” or the “Company”) (
NASDAQ:Z) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
YSS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws ViolationsNEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of York Space Systems Inc. (“York Space Systems” or the “Company”) (
NYSE:YSS) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Qiagen N.V. (“Qiagen” or the “Company”) (
NYSE:QGEN) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
CTEV SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws ViolationsNEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Claritev Corporation (“Claritev” or the “Company”) (
NYSE:CTEV) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
CALX INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Calix, Inc.NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Calix, Inc. (“Calix” or the “Company”) (
NYSE:CALX) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
OPCH INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Option Care Health, Inc.NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Option Care Health, Inc. (“Option Care Health” or the “Company”) (
NASDAQ:OPCH) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
Mason Street Wealth Management Introduces Vision-First Retirement Planning Approach to Help Clients Build Financial ConfidenceFresno, CA, May 21, 2026 (GLOBE NEWSWIRE) -- Mason Street Wealth Management, a leading financial services firm specializing in retirement planning, highlights its innovative vision-first financial strategy, designed to help individuals approaching retirement turn their ideal future into a structured, actionable plan. By prioritizing personal goals before financial products, the firm is redefining how retirement planning is approached in today’s evolving financial landscape.
Anker Innovations Announces Multi-Year Partnership with TomorrowlandA multi-year partnership centered on “Ultimate Connection” through music, technology, and unforgettable live experiences
Carolina Financial Services Group Tackles Retirement’s “Double Threat”: How Tax and Healthcare Risks Impact RetireesGreenville, NC, May 21, 2026 (GLOBE NEWSWIRE) -- Carolina Financial Services Group, a Registered Investment Advisor firm with more than 30 years of experience in the Greenville and eastern North Carolina region as well as in the entire East Coast, is addressing the critical need for retirees to mitigate taxation and healthcare costs through a specialized, tech-enabled planning process.
Licensing Expo Concludes with Record-Breaking Show Floor and Participation from Cultural Icons, Cementing Status as Global Epicenter for Brand Collaboration130 first-time exhibitors signal explosive growth across sports, gaming, and food & beverage, while industry heavyweights converged to shape the next wave of consumer products
Anker Unveils Next-Generation Products Across Brands at Anker Day 2026From immersive audio to smart home security, Anker Innovations' portfolio debuts breakthrough technology at annual showcase
GEHC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving GE HealthCare Technologies Inc.NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (
NASDAQ:GEHC) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
ATEC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alphatec Holdings, Inc.NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Alphatec Holdings, Inc. (“Alphatec” or the “Company”) (
NASDAQ:ATEC) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
POET SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of POET Technologies Inc. Investors - Contact Kirby McInerney LLP by June 29, 2026NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased POET Technologies Inc. (“POET” or the “Company”) (
NASDAQ:POET) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
EMGA arranges USD 15m financing for Asia Alliance Bank from OeEBLONDON, May 21, 2026 (GLOBE NEWSWIRE) -- Emerging Markets Global Advisory LLP is delighted to announce yet another closing in Uzbekistan having secured funding from OeEB, the Development Bank of Austria, to support Asia Alliance Bank.
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s DiseaseCAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced topline results from the Phase 2b LUMA study evaluating BIIB122 (DNL151), an investigational small molecule inhibitor of LRRK2 (leucine-rich repeat kinase 2), in individuals with early-stage Parkinson’s disease. Results from the study show that BIIB122 did not slow the progression of Parkinson’s disease versus placebo, as measured by the primary endpoint of Time to Confirmed Worsening in the modified Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part II and III combined score. Secondary endpoints also did not show a benefit with BIIB122. Exploratory biomarker endpoints demonstrated >90% kinase inhibition of peripheral LRRK2 (phosphoserine 935) and, in a cerebrospinal fluid (CSF) sub-study, up to approximately 30% reduction observed in a biomarker of LRRK2 activity (phosphorylated Rab10). Expected levels of BIIB122 in the blood and CSF were sustained across the study. BIIB122 was generally well tolerated with an acceptable safety profile. Based on these results, Biogen and Denali will discontinue further development of BIIB122 in idiopathic Parkinson’s disease. Denali will continue to independently conduct the Phase 2a BEACON study evaluating the small molecule inhibitor in carriers of a pathogenic LRRK2 variant.
Samba TV Launches Project Gravity, an Independent Data Activation Platform for the Agentic EraProject Gravity provides advertisers and data owners with a neutral platform that onboards and activates their first party data across Google DV360, The Trade Desk, Meta, TikTok, Amazon, Magnite, and many other Samba partners
nVent to Participate in Upcoming Investor ConferenceLONDON, May 21, 2026 (GLOBE NEWSWIRE) -- nVent (
NYSE: NVT), a global leader in electrical connection and protection solutions, today announced its participation in William Blairs 46th Annual Growth Stock Conference on Wednesday, June 3, 2026. Beth Wozniak, Chair and Chief Executive Officer, will present at 8:00 a.m. CST.
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual MeetingHighlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing TumorsBOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (
NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today reported first-in-human clinical imaging and dosimetry data for AKY-2519, a miniprotein radioconjugate targeting B7-H3 expressing tumors. The data from two separate assessments of AKY-2519 – a clinical imaging and dosimetry assessment in patients with mCRPC and a clinical imaging assessment in patients with various solid tumor types – demonstrated robust tumor uptake and limited normal tissue exposure. These findings, which supported the advancement of a broad clinical development program for AKY-2519, will be presented in two poster presentations at the upcoming 2026 ASCO Annual Meeting, being held May 29 – June 2, 2026, in Chicago.
SPORTRADAR LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sportradar Group AG and Encourages Investors to Contact the FirmNEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sportradar (SRAD) To Contact Him Directly To Discuss Their Options
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical MutationsCAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced positive results from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) non-classical mutations (NCMs). These data will be presented by Julia Rotow, M.D., Clinical Director, Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, at the 2026 American Society of Clinical Oncology® (ASCO®) Annual Meeting on Saturday, May 30, 2026, 1:15 PM-2:45 PM CDT.
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.
Equus Announces First Quarter Net Asset ValueHOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Equus Total Return, Inc. (
NYSE: EQS) (“Equus” or the “Company”) reports net assets as of March 31, 2026, of $20.9 million. Net asset value per share increased to $1.50 as of March 31, 2026, from $1.19 as of December 31, 2025. Comparative data is summarized below (in thousands, except per share amounts):
Whale Dynamic Joins Hitch Open World AI Championships as Official Mapping Technology Partner, Delivering Centimeter-Accurate HD Map of Tianmen Mountain for 2026 Racing SeasonSAN FRANCISCO and SHENZHEN, China and ZHANGJIAJIE, China, May 21, 2026 (GLOBE NEWSWIRE) -- Hitch Open World AI Championships and Whale Dynamic today announced that their strategic partnership has entered full-scale delivery. Whale Dynamic will provide all Hitch Open competing teams with a centimeter-accurate 3D high-definition (HD) map covering the entire 10.77-kilometer Tianmen Mountain course—featuring 1,100 meters of elevation change and 99 consecutive hairpin turns—as the unified localization baseline for the Hitch Open World AI Racing Championships 2026, scheduled for June 25–26 in Zhangjiajie, China.
North American Construction Group Ltd. Announces Voting Results of Annual and Special Meeting of ShareholdersACHESON, Alberta, May 21, 2026 (GLOBE NEWSWIRE) -- North American Construction Group Ltd. (“NACG” or “the Company”) (TSX:NOA/NYSE:NOA) today announced the results of its Annual and Special Meeting of Shareholders held on May 20, 2026. Shareholders elected directors, approved the appointment of KPMG LLP as the independent auditors of the Company, approved a non-binding advisory vote regarding the Company’s approach to executive compensation and ratified an Advance Notice Bylaw. The following are the results of the votes held at the meeting:
Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical OncologyMILLBRAE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the publication of full-text abstracts from its lead programs to be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago beginning on 29 May 2026. The six accepted presentations highlight clinical progress across Eikon’s pipeline, including the TLR7 and TLR8 dual-agonist EIK1001 trials in NSCLC and advanced melanoma, updated data for its highly selective PARP1 inhibitor EIK1003, and early development progress for the WRN inhibitor candidate EIK1005.
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant –
AerSale Announces Participation at the 2026 Jefferies Aftermarket MRO Virtual SummitMIAMI, May 21, 2026 (GLOBE NEWSWIRE) -- AerSale Corporation (
NASDAQ: ASLE) (the “Company”), today announced that the Company’s Chief Financial Officer, Martin Garmendia will present at the 2026 Jefferies Aftermarket MRO Virtual Summit on Thursday, May 28, 2026 at 12:10 pm ET, as well as host investor meetings.
Legend Biotech Announces Presentations at ASCO 2026SOMERSET, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (
NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, including a rapid oral presentation highlighting preliminary Phase 1 data for LB2102, its investigational DLL3-targeted CAR-T therapy for relapsed or refractory small-cell lung cancer (SCLC) and large-cell neuroendocrine carcinoma (LCNEC).
Navient declares second quarter common stock dividendHERNDON, Va., May 21, 2026 (GLOBE NEWSWIRE) -- Navient (Nasdaq: NAVI) announced that its board of directors approved a 2026 second quarter dividend of $0.16 per share on the company's common stock.
Asher Biotherapeutics Announces Two Presentations at the ASCO 2026 Annual Meeting Highlighting Clinical Progress Across Its CD8-Targeted Cytokine PipelineSAN MATEO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Asher Biotherapeutics (Asher Bio), a clinical-stage biotechnology company developing precisely-targeted immunotherapies for cancer, today announced two upcoming presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 – June 2, 2026 in Chicago.
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual MeetingSAN FRANCISCO, May 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced preliminary clinical data from the Phase 1 study of OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor. The data will be presented in a poster presentation on May 30, 2026 at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois. Olema will also present a trial-in-progress poster for the Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancer.
HiberCell to Present Preliminary Results from the Phase 1b Trial of GCN2 Activator HC-7366 when Combined with WELIREG® (belzutifan) for the Treatment of Late-Line Clear Cell Renal Cell Carcinoma (ccRCC) at the Upcoming 2026 ASCO Annual MeetingROSEVILLE, Minn., May 21, 2026 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics targeting the integrated stress response (ISR) to address cancer relapse, metastasis, and resistance, today announced that preliminary results from its ongoing Phase 1b study (NCT06234605) of HC-7366 in combination with WELIREG® (belzutifan), Merck’s (known as MSD outside of the United States and Canada) oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, will be presented in two poster presentations at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study is evaluating HC-7366, an activator of the ISR kinase GCN2, in patients with advanced clear cell renal cell carcinoma (ccRCC) whose disease progressed after prior PD-1/PD-L1 checkpoint inhibitor and VEGF-tyrosine kinase inhibitor (VEGF-TKI) therapy.
The Math Underlying the Success of Tort Reforms – Florida Property Insurance and BeyondCOLUMBUS, Ohio, May 21, 2026 (GLOBE NEWSWIRE) -- The favorable impact of the legislative reforms enacted in Florida is now benefiting consumers and making headlines. The reforms of 2022 began at a Special Session in April convened subsequent to Demotech’s open letter, which was released after the spring general session adjourned, without acting on the disparate, disproportionate litigation levels adversely impacting the availability and affordability of insurance in Florida’s residential property insurance market.
CVB Financial Corp. Names George A. Borba Jr. Chairman of the Board; Prior Chairman Hal W. Oswalt Transitions to Vice ChairmanONTARIO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CVB Financial Corp. (
NASDAQ: CVBF) and its principal subsidiary, Citizens Business Bank, National Association (“CBB,” and together with CVBF, the “Company”), today announced a planned leadership transition as part of its ongoing commitment to strong governance and continuity. At the conclusion of the Company’s annual meeting on May 20, 2026, it was decided that Hal W. Oswalt will transition from his role as Chairman to Vice-Chairman of the Boards of CVBF and CBB. At the same time, the Company’s Board of Directors also elected current director and Vice-Chairman George A. Borba Jr. as Chairman of the Boards of CVBF and CBB. Mr. Borba and Mr. Oswalt will assume their respective new roles immediately.
Seer Board of Directors Unanimously Rejects Further Revised Unsolicited Proposal from Radoff-JEC GroupREDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors (the “Board”) has thoroughly reviewed and unanimously rejected the further revised unsolicited non-binding proposal received on May 14, 2026, from Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), to acquire all of the outstanding shares of Seer’s Class A common stock for $2.40 per share in cash plus a contingent value right (the “May 14 Revised Proposal”).
Viral Reddit Sensation My Gums Are Bleeding Expands into Graphic Novel, Merchandise Line, and Franchise LaunchWith up to 40 million monthly views across Reddit and Instagram, cult-favorite creator Miles Erickson’s breakout comic moves from digital phenomenon to physical publishing, consumer products, and multi-platform expansion.
Mental Health Care in Utah Gets Major Boost with New Behavioral Health Center at Intermountain Health Alta View HospitalNew 56-bed Behavioral Health Center at Intermountain Alta View Hospital opens for patient care in June and doubles the number of patient beds for behavioral health care offered by Intermountain Health.
ROHM Launches ESD Protection Diodes for High-Speed Interfaces Exceeding 10 GbpsSanta Clara, CA and Kyoto, Japan, May 21, 2026 (GLOBE NEWSWIRE) -- ROHM Semiconductor today announced it has developed new Electro-Static Discharge (ESD) protection diodes – the RESDxVx series – that achieve both industry-leading low dynamic resistance (Rdyn) and ultra-low capacitance. This makes them suitable for a wide range of high-speed data communication applications.
